Copyright
©The Author(s) 2000.
World J Gastroenterol. Jun 15, 2000; 6(3): 339-343
Published online Jun 15, 2000. doi: 10.3748/wjg.v6.i3.339
Published online Jun 15, 2000. doi: 10.3748/wjg.v6.i3.339
Table 3 Median survival
Group of patients | n | Median survival (months) |
All | 336 | 2.1 |
Stage I | 51 | 11.5 |
Stage II | 205 | 2.6 |
Stage III | 80 | 0.73 |
Untreated | 245 | 1.6 |
Stage I | 26 | 7.7 |
Stage II | 146 | 1.8 |
Stage III | 73 | 0.63 |
Treated | 91 | 5.5 |
Stage I | 25 | 13.7 |
Stage II | 59 | 4.2 |
Stage III | 7 | 1.7 |
TOCE | 44 | 6.3 |
Stage I | 11 | 24.3 |
Stage II | 29 | 5.5 |
Stage III | 4 | 1.4 |
Chemotherapy (adriamycin and/or 5-FU) | 16 | 5.2 |
Multimodality therapy | 12 | 17.1 |
(PIAF/iv, chemotherapy ± TOCE ± PEI) | ||
Tamoxifen | 9 | 3.0 |
PIAF regimen chemotherapy | 5 | * |
Hepatectomy | 4 | $ |
PEI | 1 | $ |
- Citation: Sithinamsuwan P, Piratvisuth T, Tanomkiat W, Apakupakul N, Tongyoo S. Review of 336 patients with hepatocellular carcinoma at Songklanagarind Hospital. World J Gastroenterol 2000; 6(3): 339-343
- URL: https://www.wjgnet.com/1007-9327/full/v6/i3/339.htm
- DOI: https://dx.doi.org/10.3748/wjg.v6.i3.339